EMA Authorised: NovoEight (turoctocog alfa) — Novo Nordisk A/S

View source ↗

Summary

NovoEight (turoctocog alfa) by Novo Nordisk A/S has been authorised for use in Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• NovoEight (turoctocog alfa)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Novo Nordisk A/S. Decision date: 01/10/2020